Actively Recruiting
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Led by Dana-Farber Cancer Institute · Updated on 2025-06-03
5000
Participants Needed
2
Research Sites
936 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.
CONDITIONS
Official Title
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals with pathogenic or likely pathogenic germline variants in STK11, aged 30 years or older
- Individuals with pathogenic or likely pathogenic germline variants in CDKN2A, aged 40 years or older or 10 years younger than the earliest pancreatic cancer diagnosis in the family
- Individuals with pathogenic or likely pathogenic variants in other pancreatic cancer susceptibility genes (ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, EPCAM, PALB2, TP53), aged 50 years or older or 10 years younger than earliest family diagnosis, and with pancreatic cancer in at least one first- or second-degree relative from the same side of the family
- Individuals with pathogenic or likely pathogenic variants in PRSS1 and hereditary pancreatitis, aged 40 years or older or 20 years after pancreatitis onset
- Individuals with familial pancreatic cancer: family history of pancreatic cancer in two or more first-degree relatives, or one first-degree and one second-degree relative, or three or more first- and/or second-degree relatives from the same side of the family
- Individuals undergoing clinically recommended pancreatic cancer surveillance
You will not qualify if you...
- Individuals with active or prior pancreatic ductal adenocarcinoma diagnosis
- Individuals with any active metastatic cancer
- Individuals unable to give informed consent
- Individuals under 18 years old
- Individuals unable to tolerate MRI, MRCP, or Endoscopic Ultrasound procedures
- Pregnant women, though they may consent to the study later
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02215
Not Yet Recruiting
2
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
M
Matthew Yurgelun, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here